Engineering strategies and binding mechanisms of therapeutic anti-PD-1 antibodies approved by regulatory agencies globally.

Front Immunol · 2026 · PMC13233414 · PMID 42253975

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a slight trendno p-value reported

The reported immunogenicity data suggest a slight trend toward higher ADA incidence in humanized compared to fully human anti-PD-1 antibodies.

also in 4,078 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.